Basic science for the clinician 55: CTLA-4

Journal of Clinical Rheumatology

Volumn 18, Issue 3, 2012, Pages 155-158

  Sigal, Leonard H ^a  

^a Department of Emergency Medicine   (United States)

Author keywords

B7; CD152; CD28; CD80; CD86; Central supramolecular synapse; CTLA 4; Cyclin; Cyclin dependent kinase (cdk); Immunologic synapse; Immunoreceptor tyrosine based inhibitory motif (ITIM); Inducible T cell costimulator (ICOS); Major histocompatibility complex (MHC); T cell antigen receptor (TCR); Treg

Indexed keywords

ABATACEPT; BELATACEPT; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PROTEIN TYROSINE PHOSPHATASE SHP 2; TICILIMUMAB;

ARTICLE; BILIARY CIRRHOSIS; BLADDER CANCER; CD4+ CD25+ T LYMPHOCYTE; CELIAC DISEASE; DISEASE PREDISPOSITION; EYE DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LUNG NON SMALL CELL CANCER; MELANOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN POLYMORPHISM; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; CTLA-4 ANTIGEN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; POLYMORPHISM, GENETIC; T-LYMPHOCYTES;

EID: 84859741694     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31824ea103     Document Type: Article

References (34)

1. Barreto M, Ferreira RC, Lourenço L, et al. Low frequency of CD4+ CD25+ Treg in SLE patients: A heritable trait associated with CTLA4 and TGF beta gene variants. BMC Immunol. 2009;10:5.
2. Bruner JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamilyVCTLA-4. Nature. 1987;328:267-270.
3. Budarf ML, Goyette P, Boucher G, et al. A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. Genes Immun. 2011;12:51-58.
4. Carr EJ, Niederer HA, Williams J, et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet. 2009;10:121.
5. Daha NA, Kurreeman FA, Marques RB, et al. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum. 2009;60:1255-1260.
6. Davis PM, Nadler SG, Stetsko DK, et al. Abatacept modulates human dendritic cellYstimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol. 2008;126:38-47. (Pubitemid 350266453)
7. Englehardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through CD28-B7Ydependent mechanism. J Immunol. 2006;177:1052-1061. (Pubitemid 44036607)
8. Friedline RH, Brown DS, Nguyen H, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. 2009;206:421-434.
9. Khan S, Burt DJ, Ralph C, et al. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol. 2011;138:85-96.
10. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.
11. Linsley PS, Bradshaw J, Greene J, et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4:535-543. (Pubitemid 26233307)
12. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-569.
13. Madrenas J, Chau LA, Teft WA, et al. Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand. J Immunol. 2004;172:5948-5956. (Pubitemid 38621194)
14. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;CD007277.
15. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled phase 2 trial. Arthritis Rheum. 2011;63:939-948.
16. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in systemic lupus erythematosus: The results of a 12 month exploratory study. Arthritis Rheum. 2010;62:3077-3087.
17. Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol. 1996;406:209-217. (Pubitemid 26357357)
18. Park KS, Baek JA, Do JE, et al. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behçet's disease. Tissue Antigens. 2009;74:222-227.
19. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113-117.
20. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12-26.
21. Ruperto N, Lovell DJ, Quartier P, et al. Efficacy and safety of abatacept in children with juvenile idiopathic arthritis: A randomized, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383-391.
22. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792-1802.
23. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313:1972-1975. (Pubitemid 44498006)
24. Sigal LH. Basic science for clinicians 30: The immunological synapse. J Clin Rheumatol. 2005;11:234-239. (Pubitemid 41134337)
25. Sondak VK, Smalley KS, Kudchadkar R, et al. Ipilimumab. Nat Rev Drug Discov. 2011;10:411-412.
26. Stamper CC, Zhang Y, Tobin JF, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410:608-611. (Pubitemid 32267208)
27. Tivoli EA, Boriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547.
28. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends in Immunology. 2008;29:272-279.
29. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov. 2011;10:655-656.
30. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413.
31. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985-988.
32. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271-275.
33. Ying H, Yang L, Qiao G, et al. CTLA-4-B7 interaction suppresses TH17 cell differentiation. J Immunol. 2010;185:1375-1378.
34. Yokosuka T, Kobayashi W, Takamatsu M, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity. 2010;33:326-339.